NCT07494578Active, not recruiting
Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC
Multicenter Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in the Treatment of Patients With Metastatic Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
This study will enroll patients with metastatic colorectal cancer treated with the combination of Trifluridine/Tipiracile and Bevacizumab across 15 italian centers.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 17 Jul 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Colorectal cancer
- NCT number
- NCT07494578
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Jul 2025 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- ECOG PS ≥3;
- Absence of histologic diagnosis.
Who the study is looking for
- Age ≥18 years;
- ECOG PS 0-2;
- Histologic diagnosis of colorectal cancer;
- Treatment with fluoropyrimidine plus bevacizumab.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Policlinico Universitario Agostino Gemelli Coordinator of this site? Confirm its status | Rome | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.